P/B
1
BLAU3 - Blau Farmacêutica
Blau Farmaceutica is a multinational pharmaceutical company, a pioneer in biotechnology in Brazil and a strong institutional player. Its business model focuses on five specialties: oncology, hematology, infectious diseases, anesthesiology, and specialties. The company has a portfolio of highly complex drugs, including biologics, oncology, and antibiotics. Blau is present in several Latin American countries, such as Argentina, Colombia, Peru and Uruguay, and also in the United States. The hospital segment accounts for most of its net revenue.
Blau Farmaceutica is a multinational pharmaceutical company, a pioneer in biotechnology in Brazil and a strong institutional player. Its business model focuses on five specialties: oncology, hematology, infectious diseases, anesthesiology, and specialties. The company has a portfolio of highly complex drugs, including biologics, oncology, and antibiotics. Blau is present in several Latin American countries, such as Argentina, Colombia, Peru and Uruguay, and also in the United States. The hospital segment accounts for most of its net revenue.
R$2.3B
Market Cap • 9/10/2026
Novo Mercado
Listing Segment
1987
(39 years)
Founded
Cotia
Headquarters • São Paulo
Bookkeeper
5.7 • Liquidez Mínima
Índice de Liquidez • BLAU3
R$10.02
+1.52%09/10/2026
-70%BLAU3
5 years
% Total
-21%BLAU3
5 years
Annual Return
Fundamentei's price chart return accounts for all past events, such as: dividends, stock splits, bonus shares, and rights subscriptions.
DY 8,6%
DY 8,6%
1/3
The latest distribution from BLAU3 was a JCP of R$0.063 per share (ex-dividend 6/25/2026, paid 7/7/2026). The dividend yield over the last 12 months is 8,6%. Over the last 12 months there were 5 distributions, totalling R$0.867 per share.
Valuation
P/S
1,3
P/EBITDA
6
P/OCF
5,5
P/FCF
65,6
P/E
9,9
BVPS
10
EPS
1
Market Cap
Market Cap
2,3B
EV
2,3B
EV/Revenue
1,3
EV/EBITDA
5,9
EV/EBIT
7,4
Payout
Dividend Per Share
0,8
Dividend Yield
7,8%
Dividend Yield 5Y
4,4%
Payout
34,1%
Profitability
EBITDA Margin
21,5%
EBIT Margin
17,3%
Net Margin
13,1%
D&A/EBITDA
19,5%
Capex/Revenue
21,8%
Capex/D&A
518,7%
Capex/OCF
91,7%
ROE
10,1%
ROIC
10,6%
Growth
CAGR Revenue 5Y
5,5%
CAGR Op. Income 5Y
-7,5%
CAGR Net Income 5Y
-6,2%
CAGR EPS 5Y
-10,9%
CAGR OCF 5Y
22,5%
Leverage
N.D./EBITDA
—
Debt/Equity
36,8%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!